长春瑞滨联合顺铂方案治疗复发转移性乳腺癌的临床疗效及不良反应

富京, 陈晓英, 王旭

富京, 陈晓英, 王旭. 长春瑞滨联合顺铂方案治疗复发转移性乳腺癌的临床疗效及不良反应[J]. 实用临床医药杂志, 2017, (3): 68-70. DOI: 10.7619/jcmp.201703021
引用本文: 富京, 陈晓英, 王旭. 长春瑞滨联合顺铂方案治疗复发转移性乳腺癌的临床疗效及不良反应[J]. 实用临床医药杂志, 2017, (3): 68-70. DOI: 10.7619/jcmp.201703021
FU Jing, CHEN Xiaoying, WANG Xu. Clinical efficacy and side effects of vinorelbine plus cisplatin regimen in the treatment of patients with relapsed and metastatic breast cancer[J]. Journal of Clinical Medicine in Practice, 2017, (3): 68-70. DOI: 10.7619/jcmp.201703021
Citation: FU Jing, CHEN Xiaoying, WANG Xu. Clinical efficacy and side effects of vinorelbine plus cisplatin regimen in the treatment of patients with relapsed and metastatic breast cancer[J]. Journal of Clinical Medicine in Practice, 2017, (3): 68-70. DOI: 10.7619/jcmp.201703021

长春瑞滨联合顺铂方案治疗复发转移性乳腺癌的临床疗效及不良反应

基金项目: 辽宁省卫生厅资助基金。
详细信息
  • 中图分类号: R737.9

Clinical efficacy and side effects of vinorelbine plus cisplatin regimen in the treatment of patients with relapsed and metastatic breast cancer

  • 摘要: 目的 观察长春瑞滨联合顺铂方案在复发转移性乳腺癌治疗中的近期疗效和不良反应.方法 回顾性分析62例复发转移性乳腺癌患者临床资料,给予长春瑞滨联合顺铂治疗.化疗过程中记录不良反应,评价疗效.结果 治疗总有效率为59.68%(37/62),临床总获益率为90.32%(56/42),不良反应主要为骨髓抑制及胃肠道反应.结论 NP方案治疗复发转移性乳腺癌疗效确切,不良反应患者能够耐受.
    Abstract: Objective To observe the short-term efficacy and side effects of vinorelbine combined with cisplatin regimen in the treatment of patients with relapsed and metastatic breast cancer.Methods Clinical materials of 62 patients with relapsed and metastatic breast cancer were analyzed retrospectively,and they were treated with vinorelbine and cisplatin.Adverse events were recorded and efficacy was evaluated.Results The total effective rate was 59.68% (37/62).The total clinical benefit rate was 90.32% (56/42).The main adverse reactions were myelosuppression and gastrointestinal response.Conclusion NP regimen is effective in the treatment of patients with relapsed and metastatic breast cancer,and patients can tolerate the adverse reactions.
计量
  • 文章访问数:  369
  • HTML全文浏览量:  121
  • PDF下载量:  4
  • 被引次数: 0
出版历程

目录

    /

    返回文章
    返回
    x 关闭 永久关闭